These effects regarding correction of metabolic imbalances were potent and beneficial making FGF19 and FGF21 exciting new opportunities for exploring novel therapies to combat the growing diabetes and obesity epidemics. The gene discussed is FGF19; the disease is obesity due to melanocortin 4 receptor deficiency.